Xencor (XNCR) News Today $15.74 -0.05 (-0.32%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$16.43 +0.69 (+4.38%) As of 02/21/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Xencor (XNCR) to Release Quarterly Earnings on TuesdayXencor (NASDAQ:XNCR) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comXencor reports financial restatements, cites errorsFebruary 13, 2025 | msn.comEssex LLC Sells 19,000 Shares of Xencor, Inc. (NASDAQ:XNCR)Essex LLC decreased its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 113,661 shares of the biopharmaceutical company's stock after selling 19,000 shares during the quarter. EssexFebruary 9, 2025 | marketbeat.comXencor's SWOT analysis: biotech stock faces mixed outlook amid pipeline progressFebruary 5, 2025 | msn.comXencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Buy" from BrokeragesShares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been assigned an average recommendation of "Buy" from the eight brokerages that are covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the coFebruary 3, 2025 | marketbeat.comXencor (NASDAQ:XNCR investor five-year losses grow to 50% as the stock sheds US$96m this past weekFebruary 1, 2025 | finance.yahoo.comXencor, Inc. (NASDAQ:XNCR) Short Interest Up 21.4% in JanuaryXencor, Inc. (NASDAQ:XNCR - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 4,990,000 shares, an increase of 21.4% from the December 31st total of 4,110,000 shares. Based on an average daily volume of 603,100 shares, the days-to-cover ratio is presently 8.3 days.February 1, 2025 | marketbeat.comXencor: Substantial Promise, Slow ProgressJanuary 30, 2025 | seekingalpha.comXencor (NASDAQ:XNCR) Stock Price Down 3.9% - Time to Sell?Xencor (NASDAQ:XNCR) Shares Down 3.9% - Time to Sell?January 24, 2025 | marketbeat.comXencor's SWOT analysis: biotech stock navigates pipeline progress amid market challengesJanuary 23, 2025 | msn.comXencor (NASDAQ:XNCR) Trading Down 3.8% - Should You Sell?Xencor (NASDAQ:XNCR) Shares Down 3.8% - Should You Sell?January 17, 2025 | marketbeat.comBank of America Securities Remains a Buy on Xencor (XNCR)January 14, 2025 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Xencor (XNCR) and Pfizer (PFE)January 14, 2025 | markets.businessinsider.comXencor (NASDAQ:XNCR) Stock Price Down 9.3% - Should You Sell?Xencor (NASDAQ:XNCR) Trading Down 9.3% - Here's WhyJanuary 10, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Buy" by BrokeragesShares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have received a consensus rating of "Buy" from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy ratingJanuary 9, 2025 | marketbeat.com26,831 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Sanctuary Advisors LLCSanctuary Advisors LLC bought a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 26,831 shares of the biopharmaceutical company's stock, valued at approximately $540,000. Other inDecember 26, 2024 | marketbeat.comBarclays PLC Raises Stake in Xencor, Inc. (NASDAQ:XNCR)Barclays PLC raised its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 100.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 155,568 shares of the biopharmaceutical company's stock after acquiring an addiDecember 24, 2024 | marketbeat.comJane Street Group LLC Has $3.39 Million Stake in Xencor, Inc. (NASDAQ:XNCR)Jane Street Group LLC grew its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 18.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 168,431 shares of the biopharmaceutical company's stock after acquiring an addiDecember 20, 2024 | marketbeat.comState Street Corp Reduces Stake in Xencor, Inc. (NASDAQ:XNCR)State Street Corp cut its holdings in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 7.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,119,290 shares of the biopharmaceutical company's stock after selling 233,086 sharDecember 19, 2024 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Buy" by AnalystsShares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been given an average rating of "Buy" by the nine ratings firms that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendationDecember 15, 2024 | marketbeat.comXencor initiated with an Overweight at Wells FargoDecember 13, 2024 | markets.businessinsider.comXencor’s Promising Pipeline and Strategic Partnerships Drive Buy RatingDecember 13, 2024 | markets.businessinsider.comWells Fargo Initiates Coverage of Xencor (XNCR) with Overweight RecommendationDecember 13, 2024 | msn.comXencor (NASDAQ:XNCR) Coverage Initiated at Wells Fargo & CompanyWells Fargo & Company assumed coverage on shares of Xencor in a research report on Thursday. They set an "overweight" rating and a $37.00 price target on the stock.December 12, 2024 | marketbeat.comPromising Prospects for Xencor’s Plamotamab in Autoimmune Treatments Drive Buy RatingDecember 11, 2024 | markets.businessinsider.comCharles Schwab Investment Management Inc. Has $12.61 Million Holdings in Xencor, Inc. (NASDAQ:XNCR)Charles Schwab Investment Management Inc. increased its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 7.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 626,988 shares of the biopharmaceutical compDecember 9, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 98,051 Shares of Xencor, Inc. (NASDAQ:XNCR)Jacobs Levy Equity Management Inc. trimmed its stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 32.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 207,622 shares of the biopharmaceutical company's stock after selling 9December 7, 2024 | marketbeat.comPolar Asset Management Partners Inc. Acquires New Stake in Xencor, Inc. (NASDAQ:XNCR)Polar Asset Management Partners Inc. bought a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 46,700 shares of the biopharmaceutical company's stock, valued aDecember 6, 2024 | marketbeat.comInsider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 1,421 Shares of StockDecember 5, 2024 | insidertrades.comRA Capital Management L.P. Makes New Investment in Xencor, Inc. (NASDAQ:XNCR)RA Capital Management L.P. bought a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 575,000 shares of the biopharmaceutical company's stock, valued at approximately $11,563,000. RA Capital ManagemenDecember 5, 2024 | marketbeat.comReadystate Asset Management LP Buys Shares of 96,100 Xencor, Inc. (NASDAQ:XNCR)Readystate Asset Management LP purchased a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 96,100 shares of the biopharmaceutical company'sDecember 5, 2024 | marketbeat.comRTW Investments LP Takes $11.56 Million Position in Xencor, Inc. (NASDAQ:XNCR)RTW Investments LP acquired a new stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 575,000 shares of the biopharmaceutical company's stock, vaDecember 5, 2024 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Stock Position Increased by Point72 Asset Management L.P.Point72 Asset Management L.P. boosted its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 147.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,120,229 shares of the biopharmaceutical company's stockDecember 5, 2024 | marketbeat.comXencor’s Strategic Advancements and Strong Financial Outlook Justify Buy Rating and Increased Price TargetDecember 3, 2024 | markets.businessinsider.comCritical Insights From Xencor Analyst Ratings: What You Need To KnowDecember 2, 2024 | benzinga.comPiper Sandler Upgrades Xencor (XNCR)December 2, 2024 | msn.comBaker BROS. Advisors LP Grows Stake in Xencor, Inc. (NASDAQ:XNCR)Baker BROS. Advisors LP raised its position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 22.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 670,431 shares of the biopharmaceutical company's stock aftDecember 2, 2024 | marketbeat.com352,200 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Erste Asset Management GmbHErste Asset Management GmbH purchased a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 352,200 shares of the biophaDecember 2, 2024 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Sees Large Decline in Short InterestXencor, Inc. (NASDAQ:XNCR - Get Free Report) saw a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 4,100,000 shares, a drop of 18.2% from the October 31st total of 5,010,000 shares. Based on an average daily volume of 570,900 shares, the short-interest ratio is presently 7.2 days.November 30, 2024 | marketbeat.comBraidwell LP Takes Position in Xencor, Inc. (NASDAQ:XNCR)Braidwell LP acquired a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 466,448 shares of the biopharmaceutical company's stock, valuNovember 29, 2024 | marketbeat.comThrivent Financial for Lutherans Raises Holdings in Xencor, Inc. (NASDAQ:XNCR)Thrivent Financial for Lutherans lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 127.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 116,369 shares of the biopharmaceutical company's stock after purchasing anNovember 28, 2024 | marketbeat.comLoomis Sayles & Co. L P Lowers Stake in Xencor, Inc. (NASDAQ:XNCR)Loomis Sayles & Co. L P lessened its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 2.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 900,266 shares of the biopharmaceutical company's stock after selling 20,918 shares duringNovember 27, 2024 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat Sells 49,278 SharesNovember 26, 2024 | insidertrades.comXencor: Plamotamab NHL Data Leads To RA Program AdvancementNovember 22, 2024 | seekingalpha.comXencor Reports Q3 2024 Earnings and Program UpdatesNovember 21, 2024 | markets.businessinsider.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Buy" from AnalystsXencor, Inc. (NASDAQ:XNCR - Get Free Report) has earned a consensus recommendation of "Buy" from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy raNovember 20, 2024 | marketbeat.comInsider Selling: Xencor, Inc. (NASDAQ:XNCR) CEO Sells 3,366 Shares of StockNovember 15, 2024 | insidertrades.comInsider Selling: Xencor, Inc. (NASDAQ:XNCR) VP Sells 68,684 Shares of StockNovember 14, 2024 | insidertrades.comXencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%November 13, 2024 | finance.yahoo.comLeerink Partnrs Increases Earnings Estimates for XencorXencor, Inc. (NASDAQ:XNCR - Free Report) - Leerink Partnrs upped their FY2024 earnings per share estimates for shares of Xencor in a research report issued to clients and investors on Thursday, November 7th. Leerink Partnrs analyst J. Chang now forecasts that the biopharmaceutical company will poNovember 11, 2024 | marketbeat.com Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Media Mentions By Week XNCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XNCR News Sentiment▼0.000.60▲Average Medical News Sentiment XNCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XNCR Articles This Week▼13▲XNCR Articles Average Week Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Krystal Biotech News SpringWorks Therapeutics News Biohaven News Recursion Pharmaceuticals News PTC Therapeutics News Organon & Co. News Ultragenyx Pharmaceutical News Alvotech News Avidity Biosciences News ADMA Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XNCR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
